Clinical trial NCT04220125: Preoperative Ketamine and Perioperative Depression
Official title: Preoperative Ketamine as a Strategy to Decrease Perioperative Depression During the Perioperative Period: a Randomized Active Controlled Pilot Study
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Depressive Disorder
Lead sponsor: Northwestern University
Sponsor class: OTHER
First posted: 2020-01-07
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Depressive symptoms, in patients with a life history of major depressive disorder (MDD), are very common in the general population, and are especially so in elderly adults undergoing surgery.Symptoms of depression at the time of surgery is associated with risk for postoperative complications.Attenuating depressive symptoms in patients undergoing surgery is thus a plausible but not adequately tested strategy for improving patient postoperative outcomes. Conventional treatment of depression takes weeks and, therefore, is not always a realistic option, particularly when surgery is urgent. Importantly, there are currently no guidelines for diagnosing and managing MDD in surgical patients. Given its association with complications including perioperative cognitive disorders such as delirium, and over longer periods of time with dementing disorders, the feasibility and efficacy of quick-acting treatments for depressive symptoms in surgical patients are direly needed. This need is particularly acute given the rising number of elderly patients undergoing surgery who are prone to depression and surgical complications.

Aim 1: To assess the feasibility of enrolling patients in a clinical trial where a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) or midazolam (0.045 mg/kg) is given 1 to 3 days before surgery in the preoperative clinic as a strategy to improve depressive symptoms during the perioperative period.

Aim 2: To obtain estimates of the variability in improvements of depressive symptoms (increase from baseline in MADRS score ≥ 2)1 day after surgery for patients given a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) 1 to 3 days before surgery compared with midazolam 0.045 mg/kg.

Aim 3: To assess for the safety and tolerability of administration of a sub-anesthetic dose of ketamine (0.5 mg/kg over 40 min) given 1 to 3 days before surgery in the preoperative clinic (as an outpatient) by assessment of dysphoric symptoms or other complications including the need for hospitalization.

Hypothesis:

Aim 1: Hypothesis: Patients with preoperative depressive symptoms can be identified before surgery and successfully enrolled in a clinical trial comparing a sub-anesthetic dose of ketamine versus midazolam for improving perioperative depressive symptoms.

Aim 2: Hypothesis: Compared with midazolam, a sub-anesthetic dose of ketamine given preoperatively leads to an improvement in MADRS score ≥ 2 on day 1 after surgery.

Aim 3: Hypothesis: Compared with midazolam, a sub-anesthetic dose of ketamine is not associated with dysphoria or other complications.


Eligibility criteria: Inclusion Criteria:

* Male or female patients age ≥ 65 years
* Planned lumbar surgery for degenerative disc disease or spinal stenosis involving 2 or more levels
* A life history of MDD (DSM-5 criteria) and a MADRS score ≥20
* Mini-Mental State Examination (MMSE) score ≥ 15
* MMSE is between15-26
* Ability to understand English.

Exclusion Criteria:

* MMSE \< 15
* History of psychosis
* Poorly controlled hypertension
* Pre-existing aneurysmal vascular disorders
* Cocaine or other illicit drug use.

Primary outcomes:
measure: Change in depressive symptoms in the perioperative period.
timeFrame: 3 Days before surgery to 30 days after the surgical procedure
Secondary outcomes:
measure: Change in depressive symptoms 1 day after surgery
timeFrame: 24 hours after surgical procedure
measure: Safety analsysis of administration of a sub-anesthetic dose of ketamine: CADSS
timeFrame: 65 minutes after study drug has been infused.
Other outcomes:
Locations:
Study officials:
affiliation: Northwestern University
name: Charles Hogue, MD
role: PRINCIPAL_INVESTIGATOR
References: